TD Cowen on Compass Pathways (CMPS) FDA Grant: 'meaningful positive and expected in light of last Saturday’s Executive Order'
Tweet Send to a Friend
TD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
